Showing results (61-70 of 197) with videos related to

Sort By:
Pageof 20
European Journal of Cell Biology|February 5, 2011
Regulation of T cell activation by TLR ligandsHans-Heinrich Oberg, Matthias Juricke, Dieter Kabelitz, et al.
International Immunopharmacology|March 14, 2013
Regulatory functions of γδ T cellsDieter Kabelitz, Christian Peters, Daniela Wesch, et al.
Critical Reviews in Immunology|May 19, 2020
Pyrin and Hematopoietic Interferon-Inducible Nuclear Protein Domain Proteins: Innate Immune Sensors for Cytosolic and Nuclear DNAMohammad Reza Atashzar, Gholamreza Daryabor, Dieter Kabelitz, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|September 10, 2021
Targeting Citrate Carrier (CIC) in Inflammatory Macrophages as a Novel Metabolic Approach in COVID-19 Patients: A PerspectiveMahsa Eshkevar Vakili, Zahra Saleh, Dieter Kabelitz, et al.
Oncoimmunology|June 27, 2013
Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunityDieter Kabelitz, Shirin Kalyan, Hans-Heinrich Oberg, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|August 17, 2006
Transfusion-related risks of intradermal allogeneic lymphocyte immunotherapy: single cases in a large cohort and review of the literatureChristiane Kling, Jörg Steinmann, Brigitte Flesch, et al.
Cellular & Molecular Immunology|July 24, 2020
Cancer immunotherapy with γδ T cells: many paths ahead of usDieter Kabelitz, Ruben Serrano, Léonce Kouakanou, et al.
Experimental Cell Research|December 3, 2013
Differential protein-protein interactions of full length human FasL and FasL fragments generated by proteolysisMarcus Lettau, Matthias Voss, Henriette Ebsen, et al.
Expert Opinion on Therapeutic Targets|March 11, 2005
Considering Fas ligand as a target for therapyAndreas Linkermann, Jing Qian, Marcus Lettau, et al.
Cellular & Molecular Immunology|September 3, 2020
Correction to: Cancer immunotherapy with γδ T cells: many paths ahead of usDieter Kabelitz, Ruben Serrano, Léonce Kouakanou, et al.
Pageof 20